semaglutide and liver disease (Wegovy) Improves MASH in Ongoing Study Wegovy May Halt and Even

Injection for maximum potency and localized applications

Side effects range from nausea, vomiting and diarrhea to more serious complications such as pancreatitis, acute kidney injury and intestinal paralysis

The eGFR of patients across both groups were primarily between with a mean eGFR of Most patients were taking antihypertensive medication and/or lipid-lowering drugs For CV history, only data for prior heart failure was provided, and of patients in the semaglutide group had prior heart failure compared to of the placebo group

There were no labels with the persons name or clear instructions about how much to take